Sinopharm reports stable share capital in October 2025

Sinopharm Group Co. Ltd. reported its monthly movements in securities for the period ending October 31, 2025, revealing no changes in its authorized or issued share capital during the month. The company’s total authorized share capital stands at RMB3,120,656,191. This comprises RMB1,341,810,740 for H Shares and RMB1,778,845,451 for Domestic Shares. Each class of share has a par value of RMB1.

For H Shares, the number of authorized shares remained at 1,341,810,740, with total issued shares also at 1,341,810,740. Similarly, Domestic Shares maintained 1,778,845,451 authorized shares and 1,778,845,451 issued shares. No treasury shares were reported for either class.

The company, incorporated in the People's Republic of China, notes that the concept of "authorized share capital" is not applicable in its jurisdiction. The report, submitted by company secretary Wu Yijian on November 6, 2025, indicates a static period for the company's capital structure.